1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - General
Pfizer Inc.

Pfizer Inc.

PFE.TO
Pfizer Inc.CA flagToronto Stock Exchange
12.63
CAD
+0.11
- -
71.99BMarket Cap
Pfizer Inc.
PFE.TO
(Toronto Stock Exchange)

Recent

price

12.63

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
2.75
2.65
2.49
2.57
2.65
2.69
2.95
2.99
2.36
2.49
2.55
4.93
6.13
3.58
3.81
3.74
3.8
Revenue per Share
0.35
0.43
0.66
1.1
0.49
0.38
0.4
1.21
0.64
0.98
0.56
1.33
1.9
0.13
0.48
0.46
0.26
Basic EPS, GAAP
0.42
0.8
0.7
0.81
0.83
0.73
0.79
0.83
0.79
0.62
0.71
1.81
1.58
0.29
0.59
0.54
0.66
Free Cash Flow per Basic Share
0.26
0.27
0.3
0.33
0.35
0.38
0.41
0.44
0.46
0.49
0.52
0.53
0.54
0.56
0.57
0.58
0.58
Dividend per Share
10.95
10.84
11.16
11.92
11.33
10.48
9.81
11.92
11.09
11.41
11.36
13.74
17.03
15.77
15.56
15.21
14.95
Book Value per Share
-1.72
-1.8
-1.04
-0.88
-0.95
-3.87
-7.84
-5.59
-4.41
-3.44
-2.63
0.51
0.16
-7.73
-6.31
-6.77
-5.84
Tangible Book Value per Share
23,664
23,019
21,915
20,063
18,688
18,187
17,931
17,580
17,292
16,399
16,358
16,494
16,514
16,617
16,679
16,735
16,762
Basic Weighted Avg Shares
65,165
61,035
54,657
51,584
49,605
48,851
52,824
52,546
40,825
40,905
41,651
81,288
101,175
59,554
63,627
62,579
63,695
Sales/Revenue/Turnover
25.41
27.54
31.24
31.73
27.21
26.56
25.95
26.78
16.48
17.87
22.84
29.16
37.67
7.42
23.48
27.82
26.72
Operating Margin (%)
8,399
9,026
7,655
6,410
5,537
5,157
5,757
6,269
6,150
5,755
4,681
5,191
5,064
6,290
7,013
6,592
6,584
Depreciation Expense
8,257
10,009
14,570
22,003
9,135
6,960
7,215
21,308
11,153
16,026
9,159
21,979
31,372
2,119
8,031
7,771
4,332
Net Income, GAAP
12.17
31.54
19.76
27.4
25.49
22.2
13.45
- -
- -
5.15
5.26
7.62
9.58
- -
- -
- -
14.54
Effective Tax Rate (%)
12.67
16.4
26.66
42.65
18.42
14.25
13.66
40.55
27.32
39.18
21.99
27.04
31.01
3.56
12.62
12.42
6.8
Profit Margin (%)
31,859
31,908
35,645
32,878
34,008
14,405
7,834
10,714
18,068
-4,501
9,147
17,022
9,121
-4,461
7,363
5,914
8,712
Working Capital
38,410
34,926
31,036
30,462
31,541
27,446
30,399
32,666
32,429
34,650
35,571
34,757
31,925
60,499
56,703
60,807
60,495
LT Debt
88,265
82,621
81,678
76,620
71,622
64,998
59,840
71,656
63,758
63,447
63,473
77,462
95,916
89,288
88,497
86,775
85,492
Total Equity
9.82
9
11.32
10.19
9.07
9.57
11.67
- -
- -
6.29
8.3
20.13
27.89
- -
- -
- -
- -
Return on Invested Capital (%)
7.22
8.76
13.1
19.77
9.14
7.46
8.07
- -
- -
15.95
9.72
21.39
26.47
- -
- -
- -
5.9
Return on Capital (%)
9.29
11.78
17.83
27.94
12.38
10.24
11.62
32.58
16.56
25.33
14.5
31.3
36.3
2.29
9.06
8.9
4.98
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
3,154
3,890
2,699
LT Borrowings
60,807
59,840
60,495
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
5,686
5,699
5,699
Market Capitalization
46,664
51,665
43,285

Working Capital

FRC

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
42,898
42,822
41,358
Cash, Cash Equivalents & STI
13,596
13,075
11,698
Accounts Receivable, Net
11,874
12,585
12,490
Inventories
10,654
10,667
9,945
Total Current Liabilities
36,984
34,348
32,646
Payables & Accruals
10,788
7,636
7,685
ST Debt
3,154
3,890
2,699
Deferred Revenue
784
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
3.65%
7.22%
-1.95%
Free Cash Flow
15.28%
31.94%
-7.73%
Net Income, GAAP
51.74%
73.04%
-3.24%
Sales/Revenue/Turnover
7.1%
16.73%
-1.65%
Total Cash Common Dividend
3.49%
2.97%
2.72%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
14,878
13,283
17,701
17,764
63,627
2025
13,715
14,653
16,654
17,557
62,579
2026
14,450
15,034
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.19
- -
0.27
0.02
0.48
2025
0.18
0.17
- -
-0.1
0.46
2026
0.16
-0.01
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.14
0.14
0.14
0.14
0.57
2025
0.15
0.15
- -
0.15
0.58
2026
0.15
0.15
- -
- -
- -
Similar Companies
Haw Par Corporation Limited (HAWPF)
Ono Pharmaceutical Co., Ltd. (OPHLY)
Biogen Inc. (0R1B.L)
Hunan Jingfeng Pharmaceutical Co.,Ltd. (000908.SZ)
Chugai Pharmaceutical Co., Ltd. (CHGCY)
Eli Lilly and Company (LLY)
Business
Pfizer Inc. is a global biopharmaceutical company that discovers, develops, manufactures and commercializes innovative medicines and vaccines for patients in developed and emerging markets. Founded in 1849 by Charles Pfizer and Charles Erhart in Brooklyn, New York, the company is headquartered in New York City, New York. Pfizer’s core portfolio spans internal medicine, oncology, vaccines, inflammation and immunology, and selected established products, with offerings that include prescription medicines, preventive vaccines, biologics, small molecules and combination therapies. Its commercial products and development programs address cardiovascular and metabolic diseases, obesity, respiratory diseases, infectious diseases, cancer, immunology and other serious conditions. The company continues to advance a broad late-stage and early-stage pipeline, including programs in vaccines, oncology and internal medicine, and reported 95 total pipeline candidates as of August 4, 2026. Pfizer has recently expanded through strategic transactions, including the completion of its acquisition of Metsera in November 2025, which added obesity and cardiometabolic assets such as MET-097i, MET-233i and an oral GLP-1 candidate, and strengthened its internal medicine franchise. In 2026, Pfizer also entered a strategic global licensing and collaboration agreement with Innovent Biologics for 12 early-stage cancer medicines, including ADCs and multispecific antibodies, further reinforcing its oncology pipeline. The company operates globally across the United States, Europe and other international markets, and conducts research, development, manufacturing and commercial operations through its integrated biopharmaceutical platform and wholly owned subsidiaries.